FDA approves landmark pancreatic cancer drug that’s shown to improve survival
PUBLISHED Aug 26, 2026, 2:37 PM ET
Read, Watch or Listen
The Food and Drug Administration approved Rasonque (daraxonrasib) on August 26, 2026, marking the first targeted RAS-inhibitor therapy cleared for advanced pancreatic cancer. Manufactured by Revolution Medicines, the once-daily oral tablet is indicated for adults with metastatic pancreatic adenocarcinoma who previously received systemic therapy or cannot tolerate multi-agent chemotherapy. Approval was granted more than six months ahead of the agency's user fee deadline under Priority Review and National Priority Voucher pilot programs. In a 500-patient Phase 3 clinical trial, patients taking daraxonrasib achieved a median overall survival of 13.2 months compared to 6.7 months for standard chemotherapy. Common adverse events included skin rash, diarrhea, stomatitis, nausea, and fatigue. Oncologists view the decision as a major advancement against a malignancy causing over 52,000 U.S. deaths annually, though experts emphasize the drug is a management therapy rather than a cure.
By Emily Rhodes | JQJO News
Timeline of Events
- On April 13 2026 Phase 3 RASolute 302 trial trial met endpoints.
- On May 31 2026 trial results presented at ASCO annual meeting.
- On May 31 2026 FDA granted expanded access protocol for patients.
- On July 07 2026 EMA began expedited review of daraxonrasib.
- On July 22 2026 Revolution Medicines formally submitted NDA to FDA.
- On August 26 2026 FDA officially approved Rasonque six months early.
- On August 26 2026 Revolution Medicines scheduled commercial presentation webcast.
- By September 2026 initial commercial prescription shipments begin nationwide.
- By late 2026 European regulators issue regional marketing authorization decision.
- By 2027 clinical trials evaluate daraxonrasib in first-line combination therapies.
News Intelligence
- Immediate US impact: Patients gain immediate access to first-in-class targeted oral therapy.
- Possible long-term US impact: Validates RAS-targeted drug development platform across multiple solid tumors.
- Most affected groups: Metastatic pancreatic adenocarcinoma patients, oncologists, Revolution Medicines investors, caregivers.
- What readers should prioritize: Verify treatment eligibility criteria with qualified medical oncology providers.
Left: Highlights regulatory speed under public health initiatives expanding patient access. Center: Focuses on clinical trial survival statistics, safety, and approval. Right: Highlights innovation by private drugmakers and expedited regulatory flexibility.
publication_date: August 26, 2026 trigger_description: FDA approved Rasonque tablets for pancreatic cancer on August 26. https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer
Coverage of Story:
From Left
No left-leaning sources found for this story.
From Center
FDA approves landmark pancreatic cancer drug that’s shown to improve survival
JQJO Pharmexec Pharmacytimes MedcitynewsFrom Right
No right-leaning sources found for this story.
Comments